Chronic myeloid leukemia: A model for oncology

Annals of Hematology

Volumn 84, Issue 8, 2005, Pages 487-497

  Hehlmann, Rüdiger ^a   Berger, Ute ^a   Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myeloid leukemia; Evolution to blast crisis; Imatinib in combination; Model for oncology; Targeted therapy

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; BUSULFAN; CELECOXIB; CETUXIMAB; CYTARABINE; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; LONAFARNIB; NEW DRUG; NILOTINIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VATALANIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GENOTYPE; HUMAN; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 21744462480     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1039-z     Document Type: Review

References (90)

1. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, De Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G (2004) Imatinib and pegylated human recombinant interferon-α2b in early chronic phase chronic myeloid leukemia. Blood 104:4245-4251 1:CAS:528:DC%2BD2cXhtFaisrzJ
2. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-280 1:CAS:528:DyaL2cXhvVKrtw%3D%3D
3. Berger U, Engelich G, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R (2003) Chronic myeloid leukemia in the elderly: Long-term results from randomized trials with interferon alpha. Leukemia 17:1820-1826 1:CAS:528:DC%2BD3sXntFCiur8%3D
4. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R, and the German CML Study Group (2005) Gender aspects in chronic myeloid leukemia: Long term results from randomized studies. Leukemia (in press)
5. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P (1995) Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals. Blood 88:3118-3122
6. Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M (2001) Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 98:3074-3081 1:CAS:528:DC%2BD3MXosFynt7s%3D
7. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362-3367 1:CAS:528:DyaK1cXntFCqt78%3D
8. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283 1:CAS:528:DC%2BD3sXltFemu7k%3D
9. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller MC, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259-264 1:CAS:528:DC%2BD3sXhtFWhsw%3D%3D
10. Büsche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A, German CML Study Group (2003) Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia 17:2444-2453 14562117
11. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R (2004) United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218 1:CAS:528:DC%2BD2cXhsVCqt7k%3D
12. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18:1332-1339 1:CAS:528:DC%2BD2cXlvVehsr0%3D
13. Daley GQ, van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830 1:CAS:528:DyaK3cXhsFaqs7c%3D
14. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042 1:CAS:528:DC%2BD3MXivFGnu7o%3D
15. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 1:CAS:528:DC%2BD3MXivFGnu70%3D
16. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 2:561-566 10.1038/nm0596-561
17. Duesberg P, Rausch C, Rasnick D, Hehlmann R (1998) Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A 95:13692-13697 1:CAS:528:DyaK1cXnsVGht7s%3D
18. Duesberg P, Stindl R, Hehlmann R (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 97:14295-14300 1:CAS:528:DC%2BD3MXitVClsw%3D%3D
19. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13:1825-1832 1:CAS:528:DyaK1MXnvVKgurg%3D
20. Fabarius A, Hehlmann R, Duesberg PH (2003) Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 143:59-72 1:CAS:528:DC%2BD3sXjsVWnsbk%3D
21. Forkner CE, Scott TFM (1931) Arsenic as a therapeutic agent in chronic myelogenous leukemia. Preliminary report. JAMA 97:3-5
22. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246 1:CAS:528:DC%2BD2cXpsVGqu7w%3D
23. Gale RP, Hehlmann R, Zhang M-J, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM, German CML Study Group (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810-1819 1:CAS:528:DyaK1cXht12gt7k%3D
24. Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F (2003) Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102:4298-4305 10.1182/blood-2003-04-1010
25. George DJ, Kaelin WG Jr (2003) The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349:419-421 10.1056/NEJMp030061
26. Gilliland DG, Tallman MS (2002) Focus on acute leukemias. Cancer Cell 1:417-420 10.1016/S1535-6108(02)00081-8
27. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Prezpiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536 1:CAS:528:DyaK2sXjvFCkt7g%3D
28. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880 10.1126/ science.1062538
29. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A (2002) Current trends in hematopoietic stem cell transplantation in Europe. Blood 100:2374-2386 10.1182/blood-2002-03-0675
30. Gratwohl A, Hermans J, Goldman JM, Frassoni F, Devergie A, Carreras E, Kolb HJ, Gahrton G, Arcese W, Vernant JP, Ruutu T, de Witte T, van Rhee F, Apperley J, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087-1092 10.1016/S0140-6736(98)03030-X
31. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850-858 10.1093/jnci/90.11.850
32. Hasford J, Pfirrmann M, Hochhaus A (2005) How long will chronic myeloid leukemia patients treated with imatinib live? Leukemia 19:497-499 10.1038/sj.leu.2403686
33. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald J, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiβ J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H, German CML Study Group (2003) Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): Prolongation of survival by the combination of interferon α and hydroxyurea. Leukemia 17:1529-1537 10.1038/sj.leu.2403006
34. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077 1:CAS:528:DyaK2MXislShtrw%3D
35. Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia. Ann Hematol 79:345-354 10.1007/s002770000167
36. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D
37. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983) Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306:239-242 10.1038/306239a0
38. Hochhaus A, Fischer T, Brümmendorf T, Bostel T, Burchert A, Neubauer A, Rose MT, Gschaidmeier H, Hehlmann R (2003) Combination therapy of chronic myelogenous leukemia (CML) with imatinib and pegylated interferon α2a. Proc Am Soc Clin Oncol 22:569
39. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196 10.1038/sj.leu.2402741
40. Hochhaus A, La Rosée P (2004) Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 18:1321-1331 10.1038/sj.leu.2403426
41. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP, German CML Study Group and the UK MRC CML Study Group (2000) Molecular heterogeneity in complete cytogenetic responders after interferon alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. Blood 95:62-66 1:CAS:528:DC%2BD3cXhslKjtQ%3D%3D
42. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432 10.1056/NEJMoa030513
43. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 10.1056/NEJMoa032691
44. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657-667 10.1056/NEJMoa040258
45. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 10.1200/JCO.2004.11.022
46. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007 10.1182/blood.V97.7.1999
47. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652 10.1056/NEJMoa011573
48. Kantarjian H, Talpaz M, O'Brien S, Gracia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878 10.1182/blood-2003-11-3800
49. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M (2003) Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-1041 10.1002/cncr.11223
50. Kluin-Nelemans HC, Buck G, Le Cessie S, Richards S, Beverloo HB, Falkenburg JH, Littlewood T, Muus P, Bareford D, van der Lelie H, Green AR, Roozendaal KJ, Milne AE, Chapman CS, Shepherd P, MRC and HOVON groups (2004) Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: Prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 103:4408-4415 10.1182/blood-2003-10-3605
51. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465 1:STN:280:By6D1M7kvVc%3D
52. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767-776 10.1182/ blood-2003-02-0342
53. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158 10.1001/jama.290.16.2149
54. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ (2002) In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30:729-737 10.1016/S0301-472X(02)00836-6
55. La Rosee P, O'Dwyer ME, Druker BJ (2002) Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective. Leukemia 16:1213-1219 10.1038/ sj.leu.2402555
56. Li R, Yerganian G, Duesberg P, Krämer A, Willer A, Rausch C, Hehlmann R (1997) Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A 94:14506-14511 10.1073/pnas.94.26.14506
57. Lin F, Kirkland MA, van Rhee FV, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NC (1996) Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 18:1147-1152 1:STN:280:ByiC38nkslU%3D
58. Lipton JH, Khoroshko ND, Golenkov AK, Abdulkadyrov KM, Nair MK, Raghunadharao D, Brümmendorf T, Hooftman L, Pegasys CML Study Group (2002) A randomized multicenter comparative study of peginterferon alfa-2a (40 KD) vs interferon-alfa-2a in patients with treatment-naive chronic-phase chronic myelogenous leukemia. Blood 100(Suppl 1):782a
59. Lissauer (1865) Zwei Fälle von Leucaemie. Berl Klin Wochenschr 2:403-404
60. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 10.1056/NEJMoa040938
61. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400 10.1182/blood.V97.11.3390
62. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16:1579-1583 10.1038/sj.leu.2402680
63. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, Tendler C, PEG-Intron CML Study Group (2004) Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia 18:309-315 10.1038/sj.leu.2403217
64. Müller MC, Gattermann N, Lahaye T, Deininger MWN, Frühauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Aulitzky W, Freund M, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2003) Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 17:2392-2400 10.1038/sj.leu.2403157
65. Neumann E (1869) Ein Fall von Leukämie mit Erkrankung des Knochenmarks. Archiv Heilkunde 11:1-13
66. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1501
67. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Mahon FX, Nielsen J, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Talpaz M, Taylor K, Verhoef G, Bolton A, Capdeville R, Druker B, IRIS investigators (2003) The IRIS study: International randomized study of interferon and low-dose ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 348:994-1004 10.1056/NEJMoa022457
68. O'Brien SG, Vallance SE, Craddock C, Holyoake T, Goldman JM (2001) PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myelogenous leukemia. Blood 98(Suppl 1):846a
69. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA III, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ (2004) Inhibition of wild-type and mutant BCR-ABL by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 104:2532-2539 10.1182/blood-2004-05-1851
70. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445 10.1182/blood-2002-02-0535
71. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971 10.1182/blood-2001-12-0181
72. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Kaoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 10.1126/science.1099314
73. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA (2004) Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 125:613-620 10.1111/ j.1365-2141.2004.04955.x
74. Rasnick D, Duesberg PH (1999) How aneuploidy affects metabolic control and causes cancer. Biochem J 340(Pt 3):621-630 10.1042/0264-6021:3400621
75. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293 1:STN:280:CSuD3cnjslU%3D
76. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208 10.1200/JCO.2004.10.182
77. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer C, Talpaz M, Guilhot F, Deininger MWG, Fischer T, O'Brien SG, Stone R, Gambacorti-Passerini C, Russel N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Mora E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann L, Capdeville R, Paquette RL, Druker BJ (2002) Gleevec/GlivecTM (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539 10.1182/blood.V99.10.3530
78. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942 1:CAS:528:DC%2BD3cXms1altLc%3D
79. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401 10.1126/science.1099480
80. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763 1:STN:280:DyaK1c7hvVWrtQ%3D%3D
81. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1:665-668 10.1016/S0140-6736(84)92179-2
82. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937 10.1182/blood.V99.6.1928
83. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294-299 10.1053/j.gastro.2004.02.021
84. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1998) Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541-1548
85. Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV (2004) Efficacy of dual-specific BCR-ABL and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 18:1352-1356 10.1038/sj.leu.2403416
86. Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342-347 10.1038/sj.leu.2402041
87. Virchow R (1845) Weisses Blut. Frorieps Notizen 36:151-156
88. Virchow R (1847) Weiβes Blut (Leukämie). Archiv Pathol Anat 1:563
89. Wang L, Pearson K, Ferguson JE, Clark E (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120:990-999 10.1046/ j.1365-2141.2003.04200.x
90. Wilkens L, Flemming P, Gebel M, Bleck J, Terkamp C, Wingen L, Kreipe H, Schlegelberger B (2004) Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci U S A 101:1309-1314 10.1073/pnas.0305817101